Search research articles
Contact Us
Filters
Showing results (231-240 of 277) with videos related to
Page
of 28
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 24, 2016
A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer
David R Gandara, Natasha Leighl, Jean-Pierre Delord, et al.
Cancer Discovery
|
October 13, 2016
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation
David S Hong, Van K Morris, Badi El Osta, et al.
JCO Precision Oncology
|
July 24, 2018
Survival Outcomes by <i>TP53</i> Mutation Status in Metastatic Breast Cancer
Funda Meric-Bernstam, Xiaofeng Zheng, Maryam Shariati, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 1, 2023
First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations
Filip Janku, Tae Min Kim, Gopakumar Iyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 21, 2017
Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers
Lino Möhrmann, Helen J Huang, David S Hong, et al.
NPJ Precision Oncology
|
March 20, 2021
Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study
Apostolia Maria Tsimberidou, David S Hong, Siqing Fu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 19, 2025
Concordance between tumor tissue and plasma DNA genotyping in the NCI-MATCH trial (EAY131)
Mohamed A Gouda, Filip Janku, Ying Yuan, et al.
Investigational New Drugs
|
November 22, 2017
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience
Takeo Fujii, Rivka R Colen, Mehmet Asim Bilen, et al.
JAMA Oncology
|
November 29, 2016
Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab
Reva K Basho, Michael Gilcrease, Rashmi K Murthy, et al.
British Journal of Cancer
|
April 27, 2018
Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers
Shiraj Sen, Shumei Kato, Rishi Agarwal, et al.
Page
of 28
Search research articles
Search
Showing results (231-240 of 277) with videos related to
Sort By:
Page
of 28
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 24, 2016
A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer
David R Gandara, Natasha Leighl, Jean-Pierre Delord, et al.
Cancer Discovery
|
October 13, 2016
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation
David S Hong, Van K Morris, Badi El Osta, et al.
JCO Precision Oncology
|
July 24, 2018
Survival Outcomes by <i>TP53</i> Mutation Status in Metastatic Breast Cancer
Funda Meric-Bernstam, Xiaofeng Zheng, Maryam Shariati, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 1, 2023
First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations
Filip Janku, Tae Min Kim, Gopakumar Iyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 21, 2017
Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers
Lino Möhrmann, Helen J Huang, David S Hong, et al.
NPJ Precision Oncology
|
March 20, 2021
Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study
Apostolia Maria Tsimberidou, David S Hong, Siqing Fu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 19, 2025
Concordance between tumor tissue and plasma DNA genotyping in the NCI-MATCH trial (EAY131)
Mohamed A Gouda, Filip Janku, Ying Yuan, et al.
Investigational New Drugs
|
November 22, 2017
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience
Takeo Fujii, Rivka R Colen, Mehmet Asim Bilen, et al.
JAMA Oncology
|
November 29, 2016
Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab
Reva K Basho, Michael Gilcrease, Rashmi K Murthy, et al.
British Journal of Cancer
|
April 27, 2018
Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers
Shiraj Sen, Shumei Kato, Rishi Agarwal, et al.
Page
of 28